Global Biodegradable Stents Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

This report extensively covers different segments of Global Biodegradable Stents Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).

The global biodegradable stents market is segmented by product type, material type, end user, and geography. Product types include coronary artery stents, peripheral artery stents, and others, catering to specific vascular applications. Material types encompass polymers, metals, and others, each offering unique properties and degradation profiles. End users of biodegradable stents include hospitals, ambulatory surgical centers, and cardiac catheterization laboratories, among others, where interventional procedures are performed. Geographically, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa regions, reflecting varying adoption rates and regulatory landscapes across different regions.

These segmentation factors enable a comprehensive analysis of the global biodegradable stents market, facilitating targeted marketing strategies, product development initiatives, and market expansion efforts. Manufacturers, clinicians, and healthcare stakeholders can leverage these segmentation parameters to identify market opportunities, address unmet needs, and tailor interventions to specific patient populations and geographic regions.

Global Biodegradable Stents Segment Analysis

In this report, the Global Biodegradable Stents Market has been segmented by Product Type, Material Type, End Users, and Geography.

Global Biodegradable Stents Market, Segmentation by Product Type

The Global Biodegradable Stents Market has been segmented by Product Type into Coronary Stents, Peripheral Stents.

Coronary stents are specifically designed for the treatment of coronary artery disease (CAD), which involves the narrowing or blockage of arteries supplying blood to the heart muscle. These stents are used to support narrowed arteries and improve blood flow to the heart, thereby alleviating symptoms such as chest pain (angina) and reducing the risk of heart attacks.

Peripheral stents, on the other hand, are utilized in the treatment of peripheral artery disease (PAD), which affects arteries outside the heart, typically in the legs. PAD can lead to symptoms such as leg pain, numbness, and difficulty walking due to reduced blood flow to the legs. Peripheral stents are deployed to open narrowed or blocked arteries in the legs, restoring blood flow and improving symptoms and mobility for patients with PAD.

Coronary stents are primarily used in the management of CAD, a leading cause of morbidity and mortality worldwide, while peripheral stents address the unique challenges posed by PAD, particularly in the lower extremities. By offering specialized stent solutions for coronary and peripheral vascular diseases, manufacturers can effectively address the diverse clinical needs of patients and healthcare providers. This segmentation enables targeted product development, marketing strategies, and clinical research initiatives tailored to specific vascular indications, ultimately enhancing patient outcomes and driving market growth in the global biodegradable stents market.

Global Biodegradable Stents Market, Segmentation by Material Type

The Global Biodegradable Stents Market has been segmented by Material Type into Polymer-based Stents, Metallic Stents.

Polymer-based stents are constructed using biocompatible polymers that degrade over time within the body. These stents provide temporary structural support to diseased arteries while gradually resorbing and being absorbed by the surrounding tissue. Polymer-based stents offer advantages such as flexibility, controlled degradation rates, and reduced risk of long-term complications associated with permanent metallic implants.

In contrast, metallic stents are typically made of materials such as stainless steel, cobalt-chromium, or nitinol alloy. These stents provide durable mechanical support to narrowed or blocked arteries, maintaining vessel patency and preventing restenosis. While metallic stents are not biodegradable, they are widely used in clinical practice for their proven efficacy, durability, and track record in treating coronary and peripheral artery diseases.

Polymer-based stents offer the advantage of temporary scaffolding combined with biodegradability, making them suitable for applications where long-term foreign body presence is undesirable. Metallic stents, on the other hand, provide durable mechanical support and are preferred in cases where long-term vessel patency is required. By offering both polymer-based and metallic stent options, manufacturers can cater to the specific clinical needs and preferences of patients and healthcare providers. This segmentation enables targeted product development, customization, and clinical adoption strategies tailored to different patient populations and clinical scenarios.

Global Biodegradable Stents Market, Segmentation by End Users

The Global Biodegradable Stents Market has been segmented by End Users into Hospital, Specialty Clinics, and Ambulatory Care Centers.

Hospitals serve as the primary setting for interventional procedures involving biodegradable stents, offering comprehensive diagnostic, therapeutic, and surgical services for patients with coronary and peripheral artery diseases. These facilities are equipped with advanced imaging modalities, catheterization laboratories, and cardiac care units, enabling the delivery of specialized care and interventions for patients requiring stent placement.

Specialty clinics focusing on cardiovascular care play a vital role in the management of patients with coronary and peripheral artery diseases. These clinics provide outpatient services, diagnostic testing, and interventional procedures, including stent placement, in a specialized setting dedicated to cardiovascular health. Specialty clinics often collaborate with hospitals and academic medical centers to offer multidisciplinary care and access to treatment options, including biodegradable stents, for patients with complex cardiovascular conditions.

Ambulatory care centers offer convenient and efficient healthcare services for patients requiring outpatient procedures, including stent placement. These facilities provide a range of diagnostic and treatment services in a comfortable and accessible environment, catering to the needs of patients seeking minimally invasive interventions for coronary and peripheral artery diseases. Ambulatory care centers offer streamlined workflows, shorter wait times, and cost-effective care options, making them increasingly popular for interventional procedures such as stent implantation.

Global Biodegradable Stents Market, Segmentation by Geography

In this report, the Global Biodegradable Stents Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Biodegradable Stents Market Share (%), by Geographical Region, 2023

North America represents a significant market for biodegradable stents, driven by factors such as a high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and strong research and development activities. The region is characterized by widespread adoption of innovative medical technologies and a favorable regulatory environment, supporting market growth and product innovation.

Europe is another key region in the biodegradable stents market, with countries such as Germany, the United Kingdom, and France leading in healthcare expenditure and technological innovation. The region benefits from robust healthcare systems, academic research institutions, and collaborative efforts among industry stakeholders, fostering market expansion and adoption of biodegradable stent technologies.

The Asia Pacific region is experiencing rapid growth in the biodegradable stents market, fueled by increasing healthcare expenditure, rising prevalence of cardiovascular diseases, and expanding access to advanced medical care. Countries such as China, India, and Japan are investing in healthcare infrastructure and technology adoption, driving market opportunities for biodegradable stent manufacturers and suppliers.

The Middle East and Africa region is witnessing growing demand for biodegradable stents, driven by improving healthcare access, rising awareness of cardiovascular diseases, and government initiatives to enhance healthcare infrastructure. While the market in this region is still developing, there is significant potential for growth and investment in cardiovascular interventions and medical devices.

Latin America represents an emerging market for biodegradable stents, with countries such as Brazil, Mexico, and Argentina showing increasing adoption of advanced medical technologies and improving access to healthcare services. The region offers opportunities for market expansion due to a growing burden of cardiovascular diseases and efforts to modernize healthcare infrastructure.

This report provides an in depth analysis of various factors that impact the dynamics of Global Biodegradable Stents Market. These factors include; Market Drivers, Restraints, and Opportunities.

Drivers:

• Increasing Prevalence of Cardiovascular Diseases
• Preference for Minimally Invasive Procedures
• Increasing Healthcare Expenditure
• Focus on Patient Outcomes and Quality of Life

• Growing Aging Population - The growing aging population serves as a significant driver for the biodegradable stents market. As the global population ages, there is a corresponding increase in the prevalence of cardiovascular diseases, such as coronary artery disease (CAD) and peripheral artery disease (PAD), which are common among older adults. Aging is associated with physiological changes in the cardiovascular system, including arterial stiffness, endothelial dysfunction, and atherosclerosis, leading to an elevated risk of cardiovascular events and necessitating interventions such as stent placement. Elderly patients often present with complex vascular conditions and comorbidities, making them particularly vulnerable to the adverse effects of traditional metallic stents, such as late stent thrombosis and restenosis. Biodegradable stents offer a promising alternative for this population due to their temporary nature and potential for vessel healing and restoration. By providing transient mechanical support to diseased arteries while gradually resorbing over time, biodegradable stents reduce the risk of long-term complications associated with permanent metallic implants, making them well-suited for elderly patients with multiple comorbidities.

  The aging population represents a growing segment of healthcare consumers with unique healthcare needs and preferences. Older adults often prioritize interventions that optimize functional status, independence, and quality of life while minimizing treatment burden and adverse effects. Biodegradable stents align with these patient-centered care principles by offering improved clinical outcomes, reduced long-term complications, and enhanced quality of life compared to conventional metallic stents. As a result, there is a growing demand among elderly patients and healthcare providers for biodegradable stents as a safer and more effective treatment option for coronary and peripheral artery diseases.

Restraints:

• Clinical Efficacy and Long-Term Safety Concerns
• Technological Complexity and Manufacturing Challenges
• Limited Clinical Evidence and Adoption Barriers

• Potential for Device Thrombosis and Complications - The potential for device thrombosis and complications represents a significant restraint for the biodegradable stents market. Despite advancements in stent technology, concerns persist regarding the occurrence of device thrombosis, restenosis, and other adverse events associated with biodegradable stents. These complications may arise due to various factors, including incomplete scaffold degradation, delayed endothelialization, and inflammatory responses triggered by the stent implantation. Device thrombosis, in particular, is a serious complication characterized by the formation of blood clots within or around the stent, leading to acute vessel occlusion and potentially life-threatening consequences such as myocardial infarction or stroke. While biodegradable stents aim to mitigate the risk of late stent thrombosis associated with permanent metallic implants, concerns remain about the timing and completeness of scaffold degradation, which may affect vessel healing and predispose to thrombotic events.

  Restenosis, or the re-narrowing of the treated artery, can occur following stent placement, necessitating repeat interventions and impacting long-term clinical outcomes. Delayed endothelialization, inadequate vessel remodeling, and local inflammatory reactions may contribute to restenosis and compromise the efficacy of biodegradable stents in maintaining vessel patency over time. The potential for device thrombosis and complications poses challenges for clinicians, patients, and regulatory agencies in evaluating the safety and efficacy of biodegradable stents compared to traditional metallic stents. Addressing these concerns requires comprehensive clinical data, post-market surveillance, and risk mitigation strategies to minimize adverse events and optimize patient outcomes.

Opportunities:

• Focus on Precision Medicine and Personalized Therapies
• Expansion of Indications and Clinical Applications
• Patient Education and Empowerment

• Healthcare Policy and Reimbursement Reform - Healthcare policy and reimbursement reform present significant opportunities for the biodegradable stents market. As healthcare systems worldwide undergo transformation and strive for greater value-based care, policy and reimbursement reforms can create favorable conditions for the adoption and utilization of innovative medical technologies such as biodegradable stents. One opportunity lies in the alignment of healthcare policies and reimbursement models with patient outcomes and cost-effectiveness. Value-based reimbursement models incentivize healthcare providers to deliver high-quality care that improves patient outcomes and reduces overall healthcare costs. Biodegradable stents, with their potential to enhance patient outcomes and reduce long-term complications compared to traditional metallic stents, align well with value-based care principles. By demonstrating the clinical and economic value of biodegradable stents through real-world evidence and health economic studies, manufacturers can leverage reimbursement reforms to secure favorable coverage and reimbursement rates for their products.

  Healthcare policy and reimbursement reforms can drive innovation and market access by promoting equitable access to innovative medical technologies. Policies that support early adoption of breakthrough medical devices, streamline regulatory pathways, and facilitate market entry can accelerate the availability and adoption of biodegradable stents. Reimbursement reforms that prioritize patient access, clinical effectiveness, and healthcare cost containment create an environment conducive to investment in research and development, clinical trials, and commercialization efforts for biodegradable stents. Healthcare policy and reimbursement reforms offer opportunities for stakeholder collaboration and advocacy to shape policy decisions and reimbursement policies. Manufacturers, healthcare providers, patient advocacy groups, and policymakers can collaborate to advocate for favorable reimbursement policies, coverage decisions, and coding guidelines for biodegradable stents. By engaging in dialogue with regulatory agencies, payers, and healthcare decision-makers, stakeholders can influence policy reforms that support market access, reimbursement, and adoption of biodegradable stents.

Key players in Global Biodegradable Stents Market include,

• Boston Scientific Corporation
• ELLA
• CS, s.r.o
• Abbott
• Lepu Medical Technology Co., Ltd
• Terumo Corporation
• Kyoto Medical Planning Co., Ltd.
• QualiMed
• Elixir Medical Corporation
• ENDOCOR GmbH
• BIOTRONIK SE & Co. KG
• Amaranth Medical, Inc.
• Arterial Remodeling Technologies SA.

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis